Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2024

Open Access 01-12-2024 | Septicemia | Review

Vascular leak in sepsis: physiological basis and potential therapeutic advances

Authors: Ross R. McMullan, Daniel F. McAuley, Cecilia M. O’Kane, Jonathan A. Silversides

Published in: Critical Care | Issue 1/2024

Login to get access

Abstract

Sepsis is a life-threatening condition characterised by endothelial barrier dysfunction and impairment of normal microcirculatory function, resulting in a state of hypoperfusion and tissue oedema. No specific pharmacological therapies are currently used to attenuate microvascular injury. Given the prominent role of endothelial breakdown and microcirculatory dysfunction in sepsis, there is a need for effective strategies to protect the endothelium. In this review we will discuss key mechanisms and putative therapeutic agents relevant to endothelial barrier function.
Literature
1.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.PubMedPubMedCentralCrossRef
2.
Organization WH. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. 2020.
3.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG. Sepsis impairs microvascular autoregulation and delays capillary response within hypoxic capillaries. Crit Care. 2015;19(1):1–14.CrossRef
4.
5.
Joffre J, Hellman J, Ince C, Ait-Oufella H. Endothelial responses in sepsis. Am J Respir Crit Care Med. 2020;202(3):361–70.PubMedCrossRef
6.
7.
Fernández-Sarmiento J, Schlapbach LJ, Acevedo L, Santana CR, Acosta Y, Diana A, Monsalve MC, Carcillo JA. Endothelial damage in sepsis: the importance of systems biology. Front Pediatr. 2022;9(10):828968.CrossRef
8.
9.
Rajala R. How big is the endothelium? Comment on “spatial and temporal dynamics of the endothelium.” J Thromb Haemost. 2021;19(10):2634–5.PubMedCrossRef
10.
11.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–6.PubMedCrossRef
12.
Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res. 1996;79(5):984–91.PubMedCrossRef
13.
Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol. 2001;280(2):F193-206.PubMedCrossRef
14.
López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32(1):21–30.PubMedCrossRef
15.
Vincent JL, Privalle CT, Singer M, Lorente JA, Boehm E, Meier-Hellmann A, et al. Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX). Crit Care Med. 2015;43(1):57–64.PubMedCrossRef
16.
Boerma EC, Koopmans M, Konijn A, Kaiferova K, Bakker AJ, van Roon EN, et al. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial. Crit Care Med. 2010;38(1):93–100.PubMedCrossRef
17.
Trzeciak S, Glaspey LJ, Dellinger RP, Durflinger P, Anderson K, Dezfulian C, et al. Randomized controlled trial of inhaled nitric oxide for the treatment of microcirculatory dysfunction in patients with sepsis. Crit Care Med. 2014;42(12):2482–92.PubMedCrossRef
18.
Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. The Lancet. 1977;309(8001):18–21.CrossRef
19.
Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104(10):1114–8.PubMedCrossRef
20.
Saye JA, Singer HA, Peach MJ. Role of endothelium in conversion of angiotensin I to angiotensin II in rabbit aorta. Hypertension. 1984;6(2_pt_1):216–21.PubMedCrossRef
21.
Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84(3):869–901.CrossRefPubMed
22.
Kooij G, Van Horssen J, De Vries E. Tight junctions of the blood–brain barrier. Blood–Brain Barr Microenviron Basic Physiol Neurol Dis. 2005;38(6):47–69.
23.
24.
Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta BBA Biomembr. 2008;1778(3):660–9.CrossRef
25.
Carden D, Xiao F, Moak C, Willis BH, Robinson-Jackson S, Alexander S. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am J Physiol. 1998;275(2):385–92.
26.
Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P, et al. ADAM10 regulates endothelial permeability and T-cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res. 2008;102(10):1192–201.PubMedPubMedCentralCrossRef
27.
Hahmeyer ML, Da S, Da Silva-Santos JE. Rho-proteins and downstream pathways as potential targets in sepsis and septic shock: what have we learned from basic research. Cells. 2021;10(8):1844.PubMedPubMedCentralCrossRef
28.
Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G, et al. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem. 2007;282(33):23910–8.PubMedCrossRef
29.
Xing J, Wang Q, Coughlan K, Viollet B, Moriasi C, Zou MH. Inhibition of AMP-activated protein kinase accentuates lipopolysaccharide-induced lung endothelial barrier dysfunction and lung injury in vivo. Am J Pathol. 2013;182(3):1021–30.PubMedPubMedCentralCrossRef
30.
Haidari M, Zhang W, Chen Z, Ganjehei L, Mortazavi A, Warier N, et al. Atorvastatin preserves the integrity of endothelial adherens junctions by inhibiting vascular endothelial cadherin tyrosine phosphorylation. Exp Cell Res. 2012;318(14):1673–84.PubMedCrossRef
31.
32.
Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17(9):564–80.PubMedCrossRef
33.
Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol. 2003;4(3):225–36.PubMedCrossRef
34.
Tornavaca O, Chia M, Dufton N, Almagro LO, Conway DE, Randi AM, et al. ZO-1 controls endothelial adherens junctions, cell–cell tension, angiogenesis, and barrier formation. J Cell Biol. 2015;208(6):821.PubMedPubMedCentralCrossRef
35.
36.
Clark PR, Kim RK, Pober JS, Kluger MS. Tumor necrosis factor disrupts claudin-5 endothelial tight junction barriers in two distinct NF-κB-dependent phases. PLoS ONE. 2015;10(3):e0120075.PubMedPubMedCentralCrossRef
37.
Arnalich F, Garcia-Palomero E, López J, Jiménez M, Madero R, Renart J, et al. Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. Infect Immun. 2000;68(4):1942–5.PubMedPubMedCentralCrossRef
38.
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517–28.PubMedCrossRef
39.
Brooks D, Barr LC, Wiscombe S, McAuley DF, Simpson AJ, Rostron AJ. Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation. Eur Respir J. 2020;56(1):1901298.PubMedCrossRef
40.
Branger J, Knapp S, Weijer S, Leemans JC, Pater JM, Speelman P, et al. Role oftoll-like receptor 4 in gram-positive and gram-negative pneumonia inmice. Infect Immun. 2004;72(2):788–94.PubMedPubMedCentralCrossRef
41.
Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, Mauri D, et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci. 2009;106(7):2348–52.PubMedPubMedCentralCrossRef
42.
Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84.PubMedCrossRef
43.
44.
Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1979;234(4775):470–4.CrossRef
45.
Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330(6149):662–4.PubMedCrossRef
46.
Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind. Multicent Clin Trial JAMA. 1995;273(12):934–41.
47.
Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996;334(26):1697–702.PubMedCrossRef
48.
Melter M, Reinders MEJ, Sho M, Pal S, Geehan C, Denton MD, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000;96(12):3801–8.PubMedCrossRef
49.
Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843–5.PubMedCrossRef
50.
Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372(1):83–7.PubMedCrossRef
51.
Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood. 1999;94(5):1561–7.PubMedCrossRef
52.
Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108(6):2369–79.PubMedCrossRef
53.
Satchell SC, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 2009;296(5):947–56.CrossRef
54.
Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM. Vesiculo–vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med. 1996;183(5):1981–6.PubMedCrossRef
55.
Feng Y, Venema V, Venema RC, Tsai N, Bebzadian MA, Caldwell RB. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci. 1999;40(1):157–67.PubMed
56.
Kevil CG, Keith Payne D, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem. 1998;273(24):15099–103.PubMedCrossRef
57.
Reitsma S, Slaaf DW, Vink H, Van Zandvoort MAMJ, Oude Egbrink MGA. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Archiv. 2007;454(3):345.PubMedPubMedCentralCrossRef
58.
Rehm M, Zahler S, Lötsch M, Welsch U, Conzen P, Jacob M, et al. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. J Am Soc Anesthesiol. 2004;100(5):1211–23.CrossRef
59.
Fernández-Sarmiento J, Salazar-Peláez LM, Carcillo JA. The endothelial glycocalyx: a fundamental determinant of vascular permeability in sepsis. Pediatr Crit Care Med. 2020;21(5):e291.PubMedPubMedCentralCrossRef
60.
Woodcock TE, Woodcock TM. Revised starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108(3):384–94.PubMedCrossRef
61.
Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019;23(1):1–12.CrossRef
62.
Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2019;17(2):283–94.PubMedCrossRef
63.
Moore KH, Murphy HA, George EM. The glycocalyx: a central regulator of vascular function. Am J Physiol Regul Integr Comparative Physiol. 2021;320(4):R508–18.CrossRef
64.
Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012;18(8):1217–23.PubMedCrossRef
65.
Lipowsky HH, Lescanic A. The effect of doxycycline on shedding of the glycocalyx due to reactive oxygen species. Microvasc Res. 2013;90:80–5.PubMedCrossRef
66.
Manon-Jensen T, Multhaupt HAB, Couchman JR. Mapping of matrix metalloproteinase cleavage sites on syndecan-1 and syndecan-4 ectodomains. FEBS J. 2013;280(10):2320–31.PubMedCrossRef
67.
Anand D, Ray S, Srivastava LM, Bhargava S. Evolution of serum hyaluronan and syndecan levels in prognosis of sepsis patients. Clin Biochem. 2016;49(10–11):768–76.PubMedCrossRef
68.
Yagmur E, Koch A, Haumann M, Kramann R, Trautwein C, Tacke F. Hyaluronan serum concentrations are elevated in critically ill patients and associated with disease severity. Clin Biochem. 2012;45(1–2):82–7.PubMedCrossRef
69.
Nelson A, Berkestedt I, Bodelsson M. Circulating glycosaminoglycan species in septic shock. Acta Anaesthesiol Scand. 2014;58(1):36–43.PubMedCrossRef
70.
Hippensteel JA, Uchimido R, Tyler PD, Burke RC, Han X, Zhang F, et al. Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation. Crit Care. 2019;23(1):1–10.CrossRef
71.
Byrne L, Obonyo NG, Diab SD, Dunster KR, Passmore MR, Boon AC, et al. Unintended consequences: fluid resuscitation worsens shock in an ovine model of endotoxemia. Am J Respir Crit Care Med. 2018;198(8):1043–54.PubMedCrossRef
72.
Chappell D, Bruegger D, Potzel J, Jacob M, Brettner F, Vogeser M, et al. Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. Crit Care. 2014;18(5):1–8.CrossRef
73.
Bruegger D, Jacob M, Rehm M, Loetsch M, Welsch U, Conzen P, et al. Atrial natriuretic peptide induces shedding of endothelial glycocalyx in coronary vascular bed of guinea pig hearts. Am J Physiol Heart Circ Physiol. 2005;289(5):1993.CrossRef
74.
Jacob M, Saller T, Chappell D, Rehm M, Welsch U, Becker BF. Physiological levels of A-, B- and C-type natriuretic peptide shed the endothelial glycocalyx and enhance vascular permeability. Basic Res Cardiol. 2013;108(3):1–9.CrossRef
75.
Kang H, Duran CL, Abbey CA, Kaunas RR, Bayless KJ. Fluid shear stress promotes proprotein convertase-dependent activation of MT1-MMP. Biochem Biophys Res Commun. 2015;460(3):596–602.PubMedPubMedCentralCrossRef
76.
Rhee P, Wang D, Ruff P, Austin B, DeBraux S, Wolcott K, et al. Human neutrophil activation and increased adhesion by various resuscitation fluids. Crit Care Med. 2000;28(1):74–8.PubMedCrossRef
77.
Suzuki K, Okada H, Takemura G, Takada C, Kuroda A, Yano H, et al. Neutrophil elastase damages the pulmonary endothelial glycocalyx in lipopolysaccharide-induced experimental endotoxemia. Am J Pathol. 2019;189(8):1526–35.PubMedCrossRef
78.
van der Heijden M, van Nieuw Amerongen GP, Chedamni S, van Hinsbergh VWM, Johan Groeneveld AB. The angiopoietin-Tie2 system as a therapeutic target in sepsis and acute lung injury. Expert Opin Ther Targets. 2009;13(1):39–53.PubMedCrossRef
79.
Koh GY. Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol Med. 2013;19(1):31–9.PubMedCrossRef
80.
Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 2004;18(9):1060–71.PubMedPubMedCentralCrossRef
81.
Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103(11):4150–6.PubMedCrossRef
82.
Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest. 2016;126(9):3495–510.PubMedPubMedCentralCrossRef
83.
Thomas M, Felcht M, Kruse K, Kretschmer S, Deppermann C, Biesdorf A, et al. Angiopoietin-2 stimulation of endothelial cells induces αvβ3 integrin internalization and degradation. J Biol Chem. 2010;285(31):23842–9.PubMedPubMedCentralCrossRef
84.
Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, Eklund L, Ivaska J, Alitalo K, Saharinen P. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nat Commun. 2015;6(1):5962.PubMedCrossRef
85.
Thamm K, Schrimpf C, Retzlaff J, Idowu TO, van Meurs M, Zijlstra JG, Ghosh CC, Zeitvogel J, Werfel TA, Haller H, Parikh SM. Molecular regulation of acute Tie2 suppression in sepsis. Critic Care Med. 2018;46(9):e928–36.CrossRef
86.
Idowu TO, Etzrodt V, Pape T, Heineke J, Stahl K, Haller H, et al. Flow-dependent regulation of endothelial Tie2 by GATA3 in vivo. Intensive Care Med Exp. 2021;9(1):1–14.CrossRef
87.
Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I, et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med. 2007;35(1):199–206.PubMedCrossRef
88.
Fang Y, Li C, Shao R, Yu H, Zhang Q, Zhao L. Prognostic significance of the angiopoietin-2/angiopoietin-1 and angiopoietin-1/Tie-2 ratios for early sepsis in an emergency department. Crit Care. 2015;19(1):1–11.CrossRef
89.
David S, Mukherjee A, Ghosh CC, Yano M, Khankin EV, Wenger JB, et al. Angiopoietin-2 may contribute to multi-organ dysfunction and death in sepsis. Crit Care Med. 2012;40(11):3034.PubMedPubMedCentralCrossRef
90.
Kümpers P, Gueler F, David S, Van Slyke P, Dumont DJ, Park JK, et al. The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care. 2011;15(5):1–4.CrossRef
91.
Stiehl T, Thamm K, Kaufmann J, Schaeper U, Kirsch T, Haller H, et al. Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Crit Care Med. 2014;42(10):e654–62.PubMedCrossRef
92.
Mallat J, Rahman N, Hamed F, Hernandez G, Fischer MO. Pathophysiology, mechanisms, and managements of tissue hypoxia. Anaesth Crit Care Pain Med. 2022;41(4):101087.PubMedCrossRef
93.
Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin. 2018;34(1):63–80.PubMedCrossRef
94.
Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 2015;19(3):1–13.
95.
Tigabu BM, Davari M, Kebriaeezadeh A, Mojtahedzadeh M. Fluid volume, fluid balance and patient outcome in severe sepsis and septic shock: a systematic review. J Crit Care. 2018;48:153–9.PubMedCrossRef
96.
Boyd JH, Forbes J, Nakada T, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011;39(2):259–65.PubMedCrossRef
97.
Sadaka F, Juarez M, Naydenov S, O’Brien J. Fluid resuscitation in septic shock: the effect of increasing fluid balance on mortality. J Intensive Care Med. 2014;29(4):213–7.PubMedCrossRef
98.
Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13(8):559–71.PubMedPubMedCentralCrossRef
99.
Zandy NL, Playford M, Pendergast AM. Abl tyrosine kinases regulate cell–cell adhesion through Rho GTPases. Proc Natl Acad Sci. 2007;104(45):17686–91.PubMedPubMedCentralCrossRef
100.
Amado-Azevedo J, van Stalborch AMD, Valent ET, Nawaz K, van Bezu J, Eringa EC, et al. Depletion of Arg/Abl2 improves endothelial cell adhesion and prevents vascular leak during inflammation. Angiogenesis. 2021;24(3):677–93.PubMedPubMedCentralCrossRef
101.
102.
Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, et al. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation. 2012;126(23):2728–38.PubMedCrossRef
103.
Birukova AA, Alekseeva E, Cokic I, Turner CE, Birukov KG. Cross talk between paxillin and Rac is critical for mediation of barrier-protective effects by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol. 2008;295(4):L593-602.PubMedPubMedCentralCrossRef
104.
Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006;86(1):279–367.PubMedCrossRef
105.
Siehl J, Thiel E. C-kit, GIST, and imatinib. Target Ther Cancer. 2007;1:145–51.CrossRef
106.
Koning NJ, de Lange F, van Meurs M, Jongman RM, Ahmed Y, Schwarte LA, et al. Reduction of vascular leakage by imatinib is associated with preserved microcirculatory perfusion and reduced renal injury markers in a rat model of cardiopulmonary bypass. Br J Anaesth. 2018;120(6):1165–75.PubMedCrossRef
107.
Aman J, Peters MJL, Weenink C, van Nieuw Amerongen GP, Vonk NA. Reversal of vascular leak with imatinib. Am J Respir Crit Care Med. 2013;188(9):1171–3.PubMedCrossRef
108.
Stephens RS, Johnston L, Servinsky L, Kim BS, Damarla M. The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. Physiol Rep. 2015;3(11):e12589.PubMedPubMedCentralCrossRef
109.
Rizzo AN, Aman J, van Nieuw Amerongen GP, Dudek SM. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler Thromb Vasc Biol. 2015;35(5):1071–9.PubMedPubMedCentralCrossRef
110.
Aman J, Duijvelaar E, Botros L, Kianzad A, Schippers JR, Smeele PJ, Azhang S, Bartelink IH, Bayoumy AA, Bet PM, Boersma W. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021;9(9):957–68.PubMedPubMedCentralCrossRef
111.
Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D’Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95(5):1122–5.PubMedCrossRef
112.
Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–87.PubMedCrossRef
113.
Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor-and cAMP-mediated signaling. J Thromb Haemost. 2003;1(4):821–8.PubMedCrossRef
114.
Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, et al. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. 1995;86(7):2760–6.
115.
Rehberg S, Enkhbaatar P, Rehberg J, La E, Ferdyan N, Qi S, et al. Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor. Crit Care Med. 2012;40(6):1957.PubMedPubMedCentralCrossRef
116.
Kortenoeven MLA, Pedersen NB, Rosenbaek LL, Fenton RA. Vasopressin regulation of sodium transport in the distal nephron and collecting duct. Am J Physiol Renal Physiol. 2015;309(4):F280–99.PubMedCrossRef
117.
Rehberg S, Yamamoto Y, Sousse L, Bartha E, Jonkam C, Hasselbach AK, Traber LD, Cox RA, Westphal M, Enkhbaatar P, Traber DL. Selective V1a agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circul Physiol. 2012;303(10):H1245–54.CrossRef
118.
Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res. 1998;83(8):852–9.PubMedCrossRef
119.
Laterre PF, Berry SM, Blemings A, Carlsen JE, François B, Graves T, et al. Effect of selepressin vs placebo on ventilator-and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA. 2019;322(15):1476–85.PubMedPubMedCentralCrossRef
120.
Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic transplants of bone marrow. Transplantation. 1968;6(2):230–47.PubMedCrossRef
121.
Németh K, Leelahavanichkul A, Yuen PST, Mayer B, Parmelee A, Robey PG, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42–9.PubMedCrossRef
122.
Xu S, Zhou Z, Li H, Liu Z, Pan X, Wang F, et al. BMSCs ameliorate septic coagulopathy by suppressing inflammation in cecal ligation and puncture-induced sepsis. J Cell Sci. 2018;131(3):jcs211151.PubMed
123.
Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, et al. Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/β-catenin signaling. Stem Cells Dev. 2011;20(1):89–101.PubMedCrossRef
124.
Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS ONE. 2011;6(9):e25171.PubMedPubMedCentralCrossRef
125.
Galstyan G, Makarova P, Parovichnikova E, Kuzmina L, Troitskaya V, Gemdzhian E, et al. The results of the single center pilot randomized Russian clinical trial of mesenchymal stromal cells in severe neutropenic patients with septic shock (RUMCESS). Int J Blood Res Disord. 2018;5(1):33.
126.
Alp E, Gonen ZB, Gundogan K, Esmaoglu A, Kaynar L, Cetin A, et al. The effect of mesenchymal stromal cells on the mortality of patients with sepsis and septic shock: a promising therapy. Emerg Med Int. 2022;2022:9222379.PubMedPubMedCentralCrossRef
127.
McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, et al. Cellular immunotherapy for septic shock. A phase I clinical trial. Am J Respir Crit Care Med. 2018;197(3):337–47.PubMedCrossRef
128.
Silva JD, Su Y, Calfee CS, Delucchi KL, Weiss D, McAuley DF, et al. Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. Eur Respir J. 2021;58(1):2002978.CrossRef
129.
Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660–73.PubMedPubMedCentralCrossRef
130.
Gorman EA, Rynne J, Gardiner HJ, Rostron AJ, Bannard-Smith J, Bentley AM, Brealey D, Campbell C, Curley G, Clarke M, Dushianthan A. Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID Trial): a multicenter, randomized, controlled clinical trial. Am J Respir Crit Care Med. 2023;208(3):256–69.PubMedCrossRef
131.
Bowdish ME, Barkauskas CE, Overbey JR, Gottlieb RL, Osman K, Duggal A, Marks ME, Hupf J, Fernandes E, Leshnower BG, Golob JL. A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19. Am J Respir Crit Care Med. 2023;207(3):261–70.PubMedCrossRef
132.
Kirkham AM, Bailey AJ, Monaghan M, Shorr R, Lalu MM, Fergusson DA, Allan DS. Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval—FASTER approval. Stem Cells Transl Med. 2022;11(7):675–87.PubMedPubMedCentralCrossRef
133.
Bellingan G, Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, et al. Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial. Intensive Care Med. 2022;48:36–44.PubMedCrossRef
134.
Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–62.PubMedCrossRef
135.
Suda K, Eom J, Jaw J, Mui T, Bai N, Or C, et al. Endotoxin-induced cardiovascular dysfunction in mice: effect of simvastatin. J Appl Physiol. 2011;111(4):1118–24.PubMedCrossRef
136.
Giusti-Paiva A, Martinez MR, Felix JVC, da Rocha MJA, Carnio EC, Elias LLK, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock. 2004;21(3):271–5.PubMedCrossRef
137.
Zheng X, Zhang W, Wang Z. Simvastatin preparations promote PDGF-BB secretion to repair LPS-induced endothelial injury through the PDGFRβ/PI3K/Akt/IQGAP1 signalling pathway. J Cell Mol Med. 2019;23(12):8314–27.PubMedPubMedCentralCrossRef
138.
La Mura V, Pasarín M, Meireles CZ, Miquel R, Rodríguez-Vilarrupla A, Hide D, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology. 2013;57(3):1172–81.PubMedCrossRef
139.
La Mura V, Gagliano N, Arnaboldi F, Sartori P, Procacci P, Denti L, Liguori E, Bitto N, Ristagno G, Latini R, Dondossola D. Simvastatin prevents liver microthrombosis and sepsis induced coagulopathy in a rat model of endotoxemia. Cells. 2022;11(7):1148.PubMedPubMedCentralCrossRef
140.
Laufs U, La Fata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272(50):31725–9.PubMedCrossRef
141.
Hölschermann H, Schuster D, Parviz B, Haberbosch W, Tillmanns H, Muth H. Statins prevent NF-κB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis. 2006;185(2):240–5.PubMedCrossRef
142.
Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 2006;32:75–9.PubMedCrossRef
143.
Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med. 2013;187(7):743–50.PubMedCrossRef
144.
Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:10742484221100108.CrossRef
145.
Innocenti F, Gori AM, Giusti B, Tozzi C, Donnini C, Meo F, et al. Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department. Clin Exp Med. 2021;21(1):101–7.PubMedCrossRef
146.
Huang L, Li Y, Cheng Z, Lv Z, Luo S, Xia Y. PCSK9 promotes endothelial dysfunction during sepsis via the TLR4/MyD88/NF-κB and NLRP3 pathways. Inflammation. 2023;46(1):115–28.PubMedCrossRef
147.
Dwivedi DJ, Grin PM, Khan M, Prat A, Zhou J, Fox-Robichaud AE, Seidah NG, Liaw PC. Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis. Shock. 2016;46(6):672–80.PubMedCrossRef
148.
Ding Z, Liu S, Wang X, Deng X, Fan Y, Sun C, et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal. 2015;22(9):760–71.PubMedPubMedCentralCrossRef
149.
Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis. 2017;262:113–22.PubMedCrossRef
150.
Navarese EP, Podhajski P, Gurbel PA, Grzelakowska K, Ruscio E, Tantry U, et al. PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. J Am Coll Cardiol. 2023;81(3):224–34.PubMedPubMedCentralCrossRef
151.
Toader E, Cividjian A, Rentero N, McAllen RM, Quintin L. Cardioinhibitory actions of clonidine assessed by cardiac vagal motoneuron recordings. J Hypertens. 2008;26(6):1169–80.PubMedCrossRef
152.
Memiş D, Hekimoğlu S, Vatan I, Yandım T, Yüksel M, Süt N. Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth. 2007;98(4):550–2.PubMedCrossRef
153.
Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004;32(6):1322–6.PubMedCrossRef
154.
Xu L, Bao H, Si Y, Wang X. Effects of dexmedetomidine on early and late cytokines during polymicrobial sepsis in mice. Inflamm Res. 2013;62(5):507–14.PubMedCrossRef
155.
Yeh YC, Wu CY, Cheng YJ, Liu CM, Hsiao JK, Chan WS, et al. Effects of dexmedetomidine on intestinal microcirculation and intestinal epithelial barrier in endotoxemic rats. Anesthesiology. 2016;125(2):355–67.PubMedCrossRef
156.
Hofer S, Steppan J, Wagner T, Funke B, Lichtenstern C, Martin E, et al. Central sympatholytics prolong survival in experimental sepsis. Crit Care. 2009;13(1):1–8.CrossRef
157.
Schmidt K, Hernekamp JF, Philipsenburg C, Zivkovic AR, Brenner T, Hofer S. Time-dependent effect of clonidine on microvascular permeability during endotoxemia. Microvasc Res. 2015;101:111–7.PubMedCrossRef
158.
Roh J, Chang CL, Bhalla A, Klein C, Hsu SYT. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem. 2004;279(8):7264–74.PubMedCrossRef
159.
Aslam M, Pfeil U, Gündüz D, Rafiq A, Kummer W, Piper HM, et al. Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier failure in endothelial cell monolayers. Br J Pharmacol. 2012;165(1):208–22.PubMedPubMedCentralCrossRef
160.
Xiao F, Wang D, Kong L, Li M, Feng Z, Shuai B, et al. Intermedin protects against sepsis by concurrently re-establishing the endothelial barrier and alleviating inflammatory responses. Nat Commun. 2018;9(1):1–15.CrossRef
161.
Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di SS. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care. 2014;18(1):1–7.CrossRef
162.
Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohé J, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med. 2009;35(11):1859–67.PubMedCrossRef
163.
Hippenstiel S, Witzenrath M, Schmeck B, Hocke A, Krisp M, Krüll M, et al. Adrenomedullin reduces endothelial hyperpermeability. Circ Res. 2002;91(7):618–25.PubMedCrossRef
164.
Brell B, Temmesfeld-Wollbrück B, Altzschner I, Frisch E, Schmeck B, Hocke AC, et al. Adrenomedullin reduces Staphylococcus aureus α-toxin–induced rat ileum microcirculatory damage. Crit Care Med. 2005;33(4):819–26.PubMedCrossRef
165.
Temmesfeld-Wollbrück B, Brell B, Dávid I, Dorenberg M, Adolphs J, Schmeck B, et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. 2007;33(4):703–10.PubMedCrossRef
166.
Struck J, Hein F, Karasch S, Bergmann A. Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model. Intensive Care Med Exp. 2013;1(1):1–11.CrossRef
167.
Geven C, Peters E, Schroedter M, Struck J, Bergmann A, McCook O, et al. Effects of the humanized anti-adrenomedullin antibody adrecizumab (HAM8101) on vascular barrier function and survival in rodent models of systemic inflammation and sepsis. Shock. 2018;50(6):648–54.PubMedCrossRef
168.
Laterre PF, Pickkers P, Marx G, Wittebole X, Meziani F, Dugernier T, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med. 2021;47(11):1284–94.PubMedPubMedCentralCrossRef
169.
Zhou G, Kamenos G, Pendem S, Wilson JX, Wu F. Ascorbate protects against vascular leakage in cecal ligation and puncture-induced septic peritonitis. Am J Physiol Regul Integr Comparative Physiol. 2012;302(4):R409–16.CrossRef
170.
Nunbhakdi-Craig V, Machleidt T, Ogris E, Bellotto D, White CL III, Sontag E. Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. J Cell Biol. 2002;158(5):967–78.PubMedPubMedCentralCrossRef
171.
Dwenger A, Pape HC, Bantel C, Schweitzer G, Krumm K, Grotz M, et al. Ascorbic acid reduces the endotoxin-induced lung injury in awake sheep. Eur J Clin Invest. 1994;24(4):229–35.PubMedCrossRef
172.
Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Matsuda H, Shimazaki S. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg. 2000;135(3):326–31.PubMedCrossRef
173.
Agarwal A, Basmaji J, Fernando SM, Ge FZ, Xiao Y, Faisal H, et al. Parenteral vitamin C in patients with severe infection: a systematic review. NEJM Evidence. 2022;1(9):EVIDoa2200105.PubMedCrossRef
174.
Angé M, Castanares-Zapatero D, De Poortere J, Dufeys C, Courtoy GE, Bouzin C, et al. α1AMP-activated protein kinase protects against lipopolysaccharide-induced endothelial barrier disruption via junctional reinforcement and activation of the p38 MAPK/HSP27 pathway. Int J Mol Sci. 2020;21(15):5581.PubMedPubMedCentralCrossRef
175.
Castanares-Zapatero D, Bouleti C, Sommereyns C, Gerber B, Lecut C, Mathivet T, et al. Connection between cardiac vascular permeability, myocardial edema, and inflammation during sepsis: role of the α: 1: AMP-activated protein kinase isoform. Crit Care Med. 2013;41(12):e411–22.PubMedCrossRef
176.
Angé M, De Poortere J, Ginion A, Battault S, Dechamps M, Muccioli GG, et al. Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK. Sci Rep. 2021;11(1):1–13.CrossRef
177.
Wang X, Wu Z, He Y, Zhang H, Tian L, Zheng C, et al. Humanin prevents high glucose-induced monocyte adhesion to endothelial cells by targeting KLF2. Mol Immunol. 2018;101:245–50.PubMedCrossRef
178.
Bachar AR, Scheffer L, Schroeder AS, Nakamura HK, Cobb LJ, Oh YK, et al. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress. Cardiovasc Res. 2010;88(2):360–6.PubMedPubMedCentralCrossRef
179.
Urban C, Hayes HV, Piraino G, Wolfe V, Lahni P, O’Connor M, et al. Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice. Front Immunol. 2022;13:984298.PubMedPubMedCentralCrossRef
180.
Duguid J, O’Shaughnessy DF, Atterbury C, Maggs PB, Murphy M, Thomas D, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11–28.CrossRef
181.
Chambers LA, Chow SJ, Shaffer LET. Frequency and characteristics of coagulopathy in trauma patients treated with a low- or high-plasma-content massive transfusion protocol. Am J Clin Pathol. 2011;136(3):364–70.PubMedCrossRef
182.
Brown LM, Aro SO, Cohen MJ. A high fresh frozen plasma: packed red blood cell transfusion ratio decreases mortality in all massively transfused trauma patients regardless of admission international normalized ratio. J Trauma Acute Care Surg. 2011;71(2):S358–63.CrossRef
183.
Straat M, Müller MCA, Meijers JCM, Arbous MS, Spoelstra de Man AME, Beurskens CJP, et al. Effect of transfusion of fresh frozen plasma on parameters of endothelial condition and inflammatory status in non-bleeding critically ill patients: a prospective substudy of a randomized trial. Crit Care. 2015;19(1):163.PubMedPubMedCentralCrossRef
184.
185.
Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003;102(4):1499–505.PubMedCrossRef
186.
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276(14):11199–203.PubMedCrossRef
187.
Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105(8):3178–84.PubMedCrossRef
188.
Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996;87(2):642–7.PubMedCrossRef
189.
Robriquet L, Collet F, Tournoys A, Prangère T, Nevière R, Fourrier F, et al. Intravenous administration of activated protein C in pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res. 2006;22:7.
190.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709.PubMedCrossRef
191.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin alfa (Activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332–41.PubMedCrossRef
192.
Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. The Lancet. 2007;369(9564):836–43.CrossRef
193.
Sinha P, He J, Matthay MA, Churpek MM, Ware LB, Calfee CS. D16 advancing the science of ards and acute respiratory failure / Mini symposium the hyperinflammatory and hypoinflammatory phenotypes have divergent clinical outcomes in sepsis and differential response to activated protein C. [cited 2023 Jul 16]; Available from: www.​atsjournals.​org.
Metadata
Title
Vascular leak in sepsis: physiological basis and potential therapeutic advances
Authors
Ross R. McMullan
Daniel F. McAuley
Cecilia M. O’Kane
Jonathan A. Silversides
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2024
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-024-04875-6

Other articles of this Issue 1/2024

Critical Care 1/2024 Go to the issue

Brief Report

Extracorporeal cardiopulmonary resuscitation versus conventional CPR in cardiac arrest: an updated meta-analysis and trial sequential analysis

Research

The long-term intercorrelation between post-burn pain, anxiety, and depression: a post hoc analysis of the “RE-ENERGIZE” double-blind, randomized, multicenter placebo-controlled trial

Matters Arising

The neurovanguard concept and real-world embracement

Research

Machine learning derived serum creatinine trajectories in acute kidney injury in critically ill patients with sepsis

Review

Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update

Research

Effects of extracorporeal CO2 removal on gas exchange and ventilator settings: a systematic review and meta-analysis